Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Smad3 (p Ser423, p Ser425) Rabbit anti-Human, Mouse, Clone: ST0493, Novus Biologicals™

Rabbit Monoclonal Antibody
Supplier: Novus Biologicals NBP267513
Description
Smad3 Monoclonal specifically detects Smad3 in Human, Mouse samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
| Smad3 (p Ser423, p Ser425) | |
| Monoclonal | |
| 1 mg/mL | |
| Western Blot 1:500-1:2000, Immunohistochemistry, Immunocytochemistry/Immunofluorescence 1:50-1:200, Immunohistochemistry-Paraffin 1:50-1:500 | |
| DKFZp586N0721, DKFZp686J10186, hMAD-3, hSMAD3, HsT17436, JV15-2MGC60396, MAD homolog 3, mad protein homolog, MAD, mothers against decapentaplegic homolog 3, MAD, mothers against decapentaplegic homolog 3 (Drosophila), mad3, MADH3mad homolog JV15-2, mothers against decapentaplegic homolog 3, Mothers against DPP homolog 3, SMA- and MAD-related protein 3, SMAD 3, SMAD family member 3HSPC193, SMAD, mothers against DPP homolog 3, SMAD, mothers against DPP homolog 3 (Drosophila), Smad3 | |
| Rabbit | |
| Protein A purified | |
| Phospho Specific, Signal Transduction, Wnt Signaling Pathway | |
| 4088 | |
| Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. | |
| IgG |
| Western Blot, Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin) | |
| ST0493 | |
| Unconjugated | |
| TBS (pH7.4), 0.05% BSA, 40% Glycerol with 0.05% Sodium Azide | |
| SMAD3 | |
| Synthetic phospho-peptide corresponding to residues surrounding Ser423 and 425 of human Smad3. (SwissProt: P84022 Human; SwissProt: Q8BUN5 Mouse) | |
| 100 μL | |
| Primary | |
| Human, Mouse | |
| Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction